PI3Kδ activation, IL6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.
Arribas AJ, Napoli S, Gaudio E, Herbaux C, Cannas E, Tarantelli C, Bordone Pittau R, Cascione L, Munz N, Aresu L, Sgrignani J, Rinaldi A, Kwee I, Rossi D, Cavalli A, Zucca E, Stussi G, Stathis A, Sloss C, Davids MS, Bertoni F.
Arribas AJ, et al. Among authors: napoli s.
Blood Adv. 2024 Oct 7:bloodadvances.2023012291. doi: 10.1182/bloodadvances.2023012291. Online ahead of print.
Blood Adv. 2024.
PMID: 39374583